THR0921, a novel peroxisome proliferator-activated receptor gamma agonist, reduces the severity of collagen-induced arthritis

Arthritis Research and Therapy

Volumn 8, Issue 1, 2005, Pages

  Tomita, Tetsuya ^a   Kakiuchi, Yoshimi ^a   Tsao, Philip S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548391628     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar1856     Document Type: Article

References (43)

1. Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440.
2. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Maffia P, Patel NS, Di Paola R, Ialenti A, Genovese T, Chatterjee PK, et al.: Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor- gamma, reduces acute inflammation. Eur J Pharmacol 2004, 483:79-93.
3. Schulze-Koops H, Lipsky PE, Kavanaugh AF, Davis LS: Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis. Modulation by treatment with anti-ICAM-1 correlates with clinical benefit. J Immunol 1995, 155 5029-5037.
4. Simon AK, Seipelt E, Sieper J: Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci USA 1994, 91 8562-8566.
5. Feldmann M, Brennan FM, Maini RN: Rheumatoid arthritis. Cell 1996, 85:307-310.
6. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G: Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002, 110:1419-1427.
7. Goldring SR, Gravallese EM: Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 2000, 12 195-199.
8. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, et al.: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
9. Romas E, Gillespie MT, Martin TJ: Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 2002, 30:340-346.
10. Arend WP, Dayer JM: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis Arthritis Rheum 1995, 38:151-160.
11. Feldmann M, Elliott MJ, Woody JN, Maini RN: Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol 1997, 64:283-350.
12. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998, 41:2196-2204.
13. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003, 48:35-45.
14. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin- 1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double- blind, placebo-controlled trial. Arthritis Rheum 2002, 46:614-624.
15. Suryaprasad AG, Prindiville T: The biology of TNF blockade. Autoimmun Rev 2003, 2:346-357.
16. Tontonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994, 79:1147-1156.
17. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA: Peroxisome proliferator-activated receptor (PPAR) gamma: Adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994, 135:798-800.
18. Cuzzocrea S, Mazzon E, Dugo L, Patel NS, Serraino I, Di Paola R, Genovese T, Britti D, De Maio M, Caputi AP, Thiemermann C: Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma. Arthritis Rheum 2003, 48:3544-3556.
19. Kawahito Y, Kondo M, Tsubouchi Y, Hashiramoto A, Bishop-Bailey D, Inoue K, Kohno M, Yamada R, Hla T, Sano H: 15-deoxydelta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 2000, 106:189-197.
20. Satyavati G, Gupta A, Tandon N: Medicinal Plants of India New Delhi: ICMR Publications; 1987.
21. Chatterjee A, Pakrashi S: The Treatise on Indian Medical Plants New Delhi: Publications and Information Directorate; 1992.
22. Trentham DE, Townes AS, Kang AH: Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med 1977, 146 857-868.
23. Banda NK, Kraus D, Vondracek A, Huynh LH, Bendele A, Holers VM, Arend WP: Mechanisms of effects of complement inhibition in murine collagen-induced arthritis. Arthritis Rheum 2002, 46 3065-3075.
24. Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko M, Yamamoto K, Nakase T, Seki H, Kato K, Kaneda Y, Ochi AP: Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 1999, 42:2532-2542.
25. Hashiramoto A, Sano H, Maekawa T, Kawahito Y, Kimura S, Kusaka Y, Wilder RL, Kato H, Kondo M, Nakajima H: C-myc antisense oligodeoxynucleotides can induce apoptosis and downregulate Fas expression in rheumatoid synoviocytes. Arthritis Rheum 1999, 42:954-962.
26. Sugatani T, Alvarez U, Hruska KA: PTEN regulates RANKL- and osteopontin-stimulated signal transduction during osteoclast differentiation and cell motility. J Biol Chem 2003, 278 5001-5008.
27. Sugatani T, Alvarez UM, Hruska KA: Activin A stimulates IkappaB- alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J Cell Biochem 2003, 90:59-67.
28. Takano H, Tomita T, Toyosaki-Maeda T, Maeda-Tanimura M, Tsuboi H, Takeuchi E, Kaneko M, Shi K, Takahi K, Myoui A, et al.: Comparison of the activities of multinucleated bone-resorbing giant cells derived from CD14-positive cells in the synovial fluids of rheumatoid arthritis and osteoarthritis patients. Rheumatology (Oxford) 2004, 43:435-441.
29. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
30. Sabatini M, Bardiot A, Lesur C, Moulharat N, Thomas M, Richard I, Fradin A: Effects of agonists of peroxisome proliferator-activated receptor gamma on proteoglycan degradation and matrix metalloproteinase production in rat cartilage in vitro. Osteoarthritis Cartilage 2002, 10:673-679.
31. Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feldmann M, Maini RN: Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin Exp Immunol 1997, 107:507-512.
32. van den Berg WB: Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res 2001, 3:18-26.
33. Thornton S, Duwel LE, Boivin GP, Ma Y, Hirsch R: Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis Rheum 1999, 42:1109-1118.
34. Jiang C, Ting AT, Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
35. Fahmi H, Di Battista JA, Pelletier JP, Mineau F, Ranger P, Martel-Pelletier J: Peroxisome proliferator - activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum 2001, 44:595-607.
36. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, et al.: Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998, 393:790-793.
37. Myers LK, Rosloniec EF, Cremer MA, Kang AH: Collageninduced arthritis, an animal model of autoimmunity. Life Sci 1997, 61:1861-1878.
38. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ: The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 2000, 164:1364-1371.
39. Chu CQ, Londei M: Differential activities of immunogenic collagen type II peptides in the induction of nasal tolerance to collagen- induced arthritis. J Autoimmun 1999, 12:35-42.
40. Niizawa A, Kogure T, Hai LX, Fujinaga H, Takahashi K, Shimada Y, Terasawa K: Clinical and immunomodulatory effects of fun-boi, an herbal medicine, on collagen-induced arthritis in vivo. Clin Exp Rheumatol 2003, 21:57-62.
41. Boissier MC, Chiocchia G, Bessis N, Hajnal J, Garotta G, Nicoletti F, Fournier C: Biphasic effect of interferon-gamma in murine collagen-induced arthritis. Eur J Immunol 1995, 25 1184-1190.
42. Mauritz NJ, Holmdahl R, Jonsson R, Van der Meide PH, Scheynius A, Klareskog L: Treatment with gamma-interferon triggers the onset of collagen arthritis in mice. Arthritis Rheum 1988, 31 1297-1304.
43. Cooper SM, Sriram S, Ranges GE: Suppression of murine collagen- induced arthritis with monoclonal anti-Ia antibodies and augmentation with IFN-gamma. J Immunol 1988, 141:1958-1962.